Forian Earnings Call Transcripts
Fiscal Year 2026
-
Stockholders approved the re-domiciliation of the company from Delaware to Maryland, with no relevant questions raised and no need to consider further proposals. Final voting results will be filed with the SEC and posted online.
Fiscal Year 2025
-
Q3 2025 saw 66% revenue growth, driven by the Kyber acquisition and strong organic expansion. Net loss narrowed, adjusted EBITDA improved, and full-year revenue is expected near the high end of guidance, with continued investment in data and analytics.
-
Second-quarter revenue grew 56% year-over-year to $7.5 million, driven by the Kyber acquisition and organic growth in life sciences. Full-year 2025 revenue is projected at $28–$30 million, with adjusted EBITDA margin guidance between -$1 million and +$1 million.
-
Q1 2025 revenue grew 45% year-over-year to $7.1 million, driven by organic growth and the Kyber acquisition. Net loss and adjusted EBITDA both improved, with strong liquidity and a positive outlook for 2025 revenue and margin expansion.
Fiscal Year 2024
-
Q3 2024 revenue was $4.7M, down year-over-year, with net loss and adjusted EBITDA both declining. Improved sales momentum and the Kyber Data Science acquisition are expected to drive growth, with 2024 revenue now forecast at the top end of guidance.
-
Q2 2024 revenue was $4.8M, nearly flat year-over-year, with net loss and Adjusted EBITDA both declining. 2024 guidance was lowered due to industry-wide data disruptions and client funding issues, but new data sources and contract renewals support long-term positioning.